TOI
T2The Oncology Institute, Inc.
OverviewThe Oncology Institute, Inc. (TOI) provides comprehensive medical oncology services, including physician care, in-house pharmacy, and clinical trials, for adult
The Oncology Institute, Inc. (TOI) provides comprehensive medical oncology services, including physician care, in-house pharmacy, and clinical trials, for adult and senior cancer patients. Its 2025 revenue was split with pharmacy services at approximately 53.6% and patient services (fee-for-service and capitated arrangements) at 45.5%. TOI sells to patients directly and partners with health plans like Elevance Health, Humana, and CarePlus for value-based care.
- What They Do (Plain English & Analogies)
- The Oncology Institute (TOI) is like a specialized "general contractor" for cancer care. They manage almost every aspect of a cancer patient's treatment in their local community, rather than requiring them to go to a large hospital. This includes doctor visits, providing chemotherapy and other infusions, running their own pharmacies to dispense medications, and even offering access to cutting-edge clinical trials and patient support programs. Their main goal is to deliver high-quality cancer care efficiently and cost-effectively. They are increasingly shifting towards a "value-based care" model, where instead of simply billing for each service (like a traditional contractor), they work with health insurance plans to manage a patient's entire cancer journey for a set fee. This incentivizes them to provide the best possible care while keeping overall costs down, much like a project manager who gets paid to deliver a successful project within a budget.
- Very Brief History
- Founded in 2007 and based in Cerritos, California, The Oncology Institute has grown to become a prominent provider of oncology services. It became a public company in November 2021 through a business combination with DFP Healthcare Acquisitions Corp.. Since its inception, TOI has expanded its footprint and has been actively transitioning and expanding its focus on value-based care models.
- "Street Stereotype"
- The Oncology Institute is generally perceived by investors and analysts as a 'MedTech Long' play and a 'Data Owner' in the healthcare sector. The street views TOI as a company that is working to prove the scalability and sustainable profitability of its value-based oncology care model. Key areas of focus for this perception include the strong growth of its integrated pharmacy business and the successful integration of AI into its operational workflows to drive efficiencies and improve margins. Achieving consistent Adjusted EBITDA profitability and positive free cash flow are critical milestones for a positive rerating.
- Subsidiaries On Linked In*
- Legally, TOI has wholly-owned subsidiaries including TOI Parent, Inc., TOI Acquisition, LLC, and TOI Management, LLC. TOI Management also holds master services agreements with affiliated physician-owned professional entities (TOI PCs). Additionally, Innovative Clinical Research Institute, LLC (ICRI) is a consolidating subsidiary for clinical trials, also referred to as The Oncology Institute Clinical Research. These are primarily operational or legal entities and are not typically presented as separate consumer-facing brands on LinkedIn.
- Customer Sectors & Example Clients
- TOI's customers are primarily health plans, risk-bearing organizations such as primary care groups and Independent Physician Associations (IPAs), and adult and senior cancer patients. Specific clients mentioned include Elevance Health, Humana, and CarePlus.
- New Customers / Segments They'Re Targeting
- TOI is actively targeting new payer partnerships and expanding its delegated capitation model to manage more patient lives under value-based care arrangements. They are focused on increasing their capitated footprint, particularly through delegated arrangements, which allows them to manage the oncology benefit more comprehensively. They are also expanding their network of both TOI-affiliated and independent clinics to support their hybrid model of patient care.
- Supply Chain And Sourcing Geographies
- The company operates a Part D dispensing platform and focuses on commercial drug procurement to optimize its pharmacy mix and leverage purchasing power as it scales as a drug purchasing organization. However, the transcript and provided information do not specify the geographic origins of the drugs or the specific supply chain partners beyond general mentions of "drug manufacturers and distributors." Therefore, specific sourcing geographies cannot be credibly stated.
- Sales Geographies And Expansion Plans
- TOI currently provides medical oncology services in the United States. As of Q4 2025, they operate 80 employed sites of care across 5 states, and their Florida Oncology network platform has grown to approximately 207 physicians and advanced practice providers across their network. They have capitated contracts in California, Florida, and Nevada. They are actively expanding their delegated capitation partnership with Elevance in Florida, with plans to more than double the current partnership across the state in 2026. They also initiated capitation agreements with Humana and CarePlus in Florida in Q4 2025. The company is opportunistic about growth and has a healthy pipeline within existing markets, not necessarily needing to expand beyond current markets to hit their 2026 capitated revenue targets.
- How Key Themes May Help/Hurt
- The 'HC Data & Services' theme is a significant tailwind for TOI. As hospital profitability rebounds and CMS incentivizes value-based care and interoperability, providers like TOI are well-positioned. TOI's focus on outsourcing analytics, revenue-cycle, and specialty population management to lightweight, cloud-native vendors aligns perfectly with the theme's premise. Their expansion of Medicare Advantage (MA) bundles and ability to manage oncology episodes under capitated arrangements directly benefits from the increasing demand for cost containment and quality improvement in oncology care from payers. The pressure on health plans' Medical Loss Ratios (MLRs) actually acts as a tailwind for TOI, as it drives payers to seek partners who can provide great care and access while improving utilization.
3 Main Long-Term Bull Details
- Rapidly Scaling Value-Based Care Model: TOI's delegated capitation model is expanding significantly, evidenced by doubling its relationship with Elevance Health in Florida and initiating new contracts with Humana and CarePlus. This model addresses a massive new total addressable market (TAM) in a capital-effective manner, driving substantial capitated revenue growth and positioning it as the most prominent model for the company.
- Robust and Growing Pharmacy Business: The Part D dispensing platform is a significant and rapidly growing segment, contributing almost $270 million in total revenue and close to $50 million in gross profit for the full year 2025. Continued strong growth in pharmacy revenue, driven by increased prescription volumes and attachment rates within their network, is a key operational focus and a strong driver of profitability.
- AI-Driven Operational Efficiencies and Profitability: TOI is successfully integrating agentic AI into core business functions like prior authorizations, call centers, and revenue cycle management. This is projected to generate significant operating expense efficiencies (e.g., $2 million in SG&A savings in 2026 from AI-related efficiencies) and improve patient care metrics, enhancing productivity, reducing costs, and strengthening TOI's competitive edge.
3 Main Long-Term Bear Details
- Initial Lower Margins on New Capitated Contracts: While capitated revenue is growing rapidly, new delegated contracts initially exhibit lower margins (mid-70s MLR) compared to legacy narrow network models (mid-60s MLR). This ramp-up period for new contracts, where margins mature over several quarters, could temper overall margin expansion in the short term as TOI scales its value-based care offerings.
- Working Capital Demands and Cash Flow Volatility: Despite expecting positive free cash flow in Q4 2025 and run-rate positivity by the end of 2026, operating cash flow can fluctuate due to investments in drug inventory and working capital to support scaling dispensing activity. This indicates continued working capital demands as the pharmacy business grows and potential for cash flow volatility.
- Competition and Execution Risk in MLR Management: The oncology care market is highly competitive. Successfully maturing new capitated contracts to target MLRs requires effective patient transition to in-network providers, adherence to care pathways, and increased script attachment, posing an execution risk. Changes in drug reimbursement policies or increased competition could also pressure margins.
- Competitors And Differentiation
- TOI operates in a highly competitive oncology care market. Its differentiation strategy centers on its unique care delivery model, which combines a backbone of employed clinics and providers with a wrap network of non-employee providers. This hybrid model allows for greater control over consistency of care, adherence to National Comprehensive Cancer Network (NCCN) guidelines, and prescribing patterns, enabling them to drive better value for patients and payers. They believe this allows them to control care delivery and price contracts more competitively than others in the market. They also highlight their community-based ability to provide radiopharmaceuticals and high-level ancillary services.
- Recent Performance & What The Market'S Focused On
- TOI reported strong Q4 and full-year 2025 results, achieving its first profitable quarter as a public company from an adjusted EBITDA perspective in Q4 2025. For the full year 2025, revenue increased approximately 28% year-over-year, surpassing $500 million, with pharmacy revenue growing 49.6% and capitation revenue growing 17.2%. The company is reaffirming its expectation to achieve full-year positive adjusted EBITDA in 2026 and expects to achieve free cash flow positivity by the end of 2026. The market is focused on the continued scaling of the delegated capitation model, particularly the expansion with Elevance Health, the sustained strong growth in pharmacy revenue, and the realization of projected operating expense efficiencies from AI implementation. Investors are closely watching for the company to deliver on its guidance for full-year 2026, including revenue in the range of $630 million to $650 million and adjusted EBITDA in the range of $0 million to $9 million.
- Brands And Revenue Segments
- The primary brand is The Oncology Institute (TOI). Revenue segments for full year 2025 were: * Pharmacy Revenue: $269.2 million * Patient Services (includes both fee-for-service and capitation arrangements): $233.5 million (calculated from total revenue $502.7M - pharmacy revenue $269.2M) * Fee-for-service: $148.5 million * Capitation: $80.5 million * Clinical Trials (outsourced in 2025, but still directs patients to trials)
Bull / Bear DetailsThe Oncology Institute (TOI) presents a compelling investment case as it achieved its first positive adjusted EBITDA quarter in Q4 2025 and projects full-year p
Thesis
The Oncology Institute (TOI) presents a compelling investment case as it achieved its first positive adjusted EBITDA quarter in Q4 2025 and projects full-year profitability in 2026. Rapid expansion of its delegated capitation model, new payer partnerships, and sustained pharmacy growth, coupled with AI-driven operational efficiencies, position TOI for continued growth and free cash flow positivity by late 2026, despite initial lower margins on new contracts and seasonal Q1 losses. (Updated 2026-03-20)
Bull case
TOI achieved a significant milestone with its first positive adjusted EBITDA quarter in Q4 2025 and positive operating cash flow. The company reaffirmed its expectation for full-year positive adjusted EBITDA in 2026 and anticipates achieving free cash flow positivity by the end of 2026, signaling strong operational execution and a clear path to sustainable financial health.
The delegated capitation model is rapidly expanding, with 9 new contracts in 2025 covering 260,000 lives and the Elevance Health partnership in Florida on track to more than double in 2026. New agreements with Humana and CarePlus further expand payer partnerships, tapping into a "tremendous opportunity" in the MA market, which acts as a tailwind for TOI.
TOI delivered robust pharmacy revenue growth of 49.6% year-over-year in 2025, driven by improved attachment rates and reduced leakage. Furthermore, the company expects $2 million in SG&A savings from AI-related efficiencies in 2026 and will launch a new network portal in Q2 to enhance provider engagement and utilization management, improving overall profitability.
Bear case
While capitated revenue is growing rapidly, new delegated contracts may initially exhibit slightly higher Medical Loss Ratios (MLRs). Additionally, Q1 2026 is seasonally expected to be the lowest quarter, with an anticipated adjusted EBITDA loss of $3 million to $1 million due to patient deductible resets and lagged drug reimbursement, potentially impacting short-term profitability.
Despite positive operating cash flow in Q4 2025, the full-year 2026 free cash flow guidance remains in a negative to slightly positive range (-$15 million to $5 million). This indicates continued working capital demands, particularly for scaling dispensing activity and growth initiatives, suggesting potential for cash flow volatility before consistent positivity is achieved.
The oncology care market remains highly competitive, with evolving payer dynamics. While the MA rate cycle is a tailwind, TOI also faces minor cannibalization of fee-for-service volumes as capitated lives increase. This could temper overall revenue growth from the FFS segment and requires continuous strong execution to maintain market share and contract terms.
Bull / Bear Case
- Bear Case
- Despite recent positive adjusted EBITDA, TOI remains unprofitable on a net income basis with a negative net margin of 13.21% and a negative return on equity of 1,527.21%. New delegated contracts may initially exhibit slightly higher Medical Loss Ratios (MLRs), and Q1 2026 is seasonally expected to be the lowest quarter with an anticipated adjusted EBITDA loss of $3 million to $1 million due to patient deductible resets and lagged drug reimbursement, potentially impacting short-term profitability. While Q4 2025 saw positive operating cash flow, the full-year 2026 free cash flow guidance remains in a negative to slightly positive range (-$15 million to $5 million), indicating continued working capital demands for scaling dispensing activity and growth initiatives, suggesting potential for cash flow volatility before consistent positivity is achieved. The oncology care market remains highly competitive, with evolving payer dynamics. TOI also faces minor cannibalization of fee-for-service volumes as capitated lives increase, which could temper overall revenue growth from the FFS segment and requires continuous strong execution to maintain market share and contract terms. The impact of the Inflation Reduction Act, while minor for 2026, represents an ongoing regulatory risk.
- Bull Case
- The Oncology Institute (TOI) achieved a significant milestone with its first positive adjusted EBITDA quarter in Q4 2025 and positive operating cash flow, reaffirming expectations for full-year positive adjusted EBITDA in 2026 and free cash flow positivity by year-end. The delegated capitation model is rapidly expanding, with 9 new contracts in 2025 covering 260,000 lives and the Elevance Health partnership in Florida on track to more than double in 2026. New agreements with Humana and CarePlus further expand payer partnerships, tapping into a "tremendous opportunity" in the MA market, which acts as a tailwind for TOI. Robust pharmacy revenue grew 49.6% year-over-year in 2025, driven by improved attachment rates. Additionally, TOI expects $2 million in SG&A savings from AI-related efficiencies in 2026 and will launch a new network portal in Q2 to enhance provider engagement and utilization management, improving overall profitability and competitive positioning.
- More Compelling & Why
- Given the current valuation, the Bull Case is more compelling. TOI's Price-to-Sales (P/S) ratio of approximately 0.7x is significantly below the US Healthcare industry average of 1.2x and its estimated fair P/S of 0.8x, suggesting it is undervalued relative to its revenue generation. The strongest argument for the bull case is the clear path to full-year positive adjusted EBITDA in 2026 and free cash flow positivity by year-end, driven by the rapid expansion of its high-margin delegated capitation model and robust pharmacy growth. My view would flip to the Bear Case if the company fails to achieve its full-year 2026 adjusted EBITDA and free cash flow guidance, or if the Medical Loss Ratios on new capitated contracts do not improve as expected, indicating persistent profitability challenges.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Achieving positive free cash flow by the end of 2026, supported by EBITDA growth and improving working capital dynamics. | Positive free cash flow is crucial for long-term financial health, enabling self-funded growth and reducing reliance on external financing. It indicates efficient capital management and operational leverage. | Management commentary and reported free cash flow in Q1, Q2, and Q3 2026 earnings, specifically regarding the trajectory towards positivity by year-end. | Bullish if management provides strong indications of achieving free cash flow positivity by year-end 2026, or if interim free cash flow results show better-than-expected improvement. Bearish if the target is delayed further or if cash burn continues without significant improvement. | Company earnings calls and press releases (Q1, Q2, Q3 2026 earnings), SEC filings (10-Q, 10-K). | FactSet: Consensus free cash flow estimates; S&P Global Market Intelligence: Working capital trends. | |
| Realization of full-year positive Adjusted EBITDA for 2026, and performance of Q1 2026 Adjusted EBITDA relative to seasonal expectations. | Achieving full-year positive Adjusted EBITDA is a critical milestone for TOI, signaling sustainable profitability and validating its operating model. Q1 performance provides an early indicator of the year's trajectory. | Reported Adjusted EBITDA for Q1 2026 (expected loss of $3 million to $1 million) and management's reaffirmation or update on the full-year 2026 Adjusted EBITDA guidance ($0 million to $9 million). | Bullish if Q1 2026 Adjusted EBITDA is at the better end of or exceeds guidance (i.e., less negative or positive), and if full-year 2026 guidance is reaffirmed or raised. Bearish if Q1 2026 Adjusted EBITDA is worse than expected or full-year guidance is lowered. | Company earnings calls and press releases (Q1, Q2, Q3 2026 earnings), SEC filings (10-Q). | AlphaSense: Sentiment analysis of earnings call transcripts; Bloomberg Terminal: Analyst consensus estimates for EBITDA. | |
| Continued expansion of the delegated capitation partnership with Elevance Health in Florida, aiming to more than double current lives, and overall achievement of $150 million in capitated revenue for full-year 2026. | This is the core of TOI's value-based care strategy, driving significant top-line growth and market penetration in a capital-efficient manner. Successful expansion validates the model and accelerates the path to sustainable profitability. | Updates on the doubling of current capitated lives (~70,000) with Elevance in Florida during 2026. Progress towards the full-year 2026 capitated revenue guidance of approximately $150 million. | Bullish if Elevance partnership expansion is on track or exceeds doubling, and if capitated revenue growth demonstrates strong progress towards or surpasses the $150 million target. Bearish if expansion is slower than expected or capitated revenue growth significantly lags guidance. | Company earnings calls and press releases (Q1, Q2, Q3 2026 earnings), SEC filings (10-Q, 10-K). | State-level Medicare Advantage enrollment data (CMS.gov), industry news on payer partnerships. | HealthVerity: Payer claims data for oncology services in Florida; IQVIA: Oncology market share data. |
| Successful launch of the proprietary new network portal in Q2 2026 and realization of the projected $2 million in AI-related SG&A savings for full-year 2026. | The new portal and AI initiatives are key to improving operational efficiency, strengthening provider engagement, and driving down the medical loss ratio, directly impacting profitability and scalability. | Management commentary on the Q2 2026 launch of the network portal, and updates on the progress and realization of the $2 million in SG&A savings from AI across prior authorization, call center, and RCM. | Bullish if the network portal launches on time and management confirms strong progress towards or exceeding the $2 million SG&A savings target. Bearish if the portal launch is delayed or if AI-related savings are less than anticipated. | Company earnings calls and press releases (Q1, Q2, Q3 2026 earnings), SEC filings (10-Q). | Company website updates, industry news on healthcare technology adoption. | Thinknum: Job postings for AI/ML roles at TOI (proxy for investment/implementation); Apptopia/Sensor Tower: App downloads/usage if the portal has a public-facing app (less likely for a network portal). |
| Sustained pharmacy revenue performance in line with the second half of 2025 run rate (approximately $27 million per month) plus modest incremental growth of 3% to 5% from attachment to new capitation lives in 2026. | The Part D dispensing platform is a significant contributor to TOI's revenue and gross profit. Continued growth and improved attachment rates demonstrate successful vertical integration and operational efficiency. | Reported pharmacy revenue for Q1, Q2, and Q3 2026, and management commentary on attachment rates within new capitation lives. Performance relative to the $27 million per month run rate plus 3-5% incremental growth. | Bullish if pharmacy revenue meets or exceeds the guided run rate and incremental growth, indicating strong attachment and operational execution. Bearish if pharmacy revenue significantly underperforms the guided run rate or if attachment rates decline. | Company earnings calls and press releases (Q1, Q2, Q3 2026 earnings), SEC filings (10-Q). | Symphony Health Solutions: Prescription volume data for oncology drugs; IQVIA: Pharmacy claims data. |
Key Reported Metrics
| Metric | Why It Matters | Last Period |
|---|---|---|
| Pharmacy Revenue Growth | Pharmacy revenue is a significant and rapidly growing segment, contributing substantially to TOI's top line and gross profit. Sustained high growth indicates effective vertical integration and operational focus. | 71.1% |
| Capitated Revenue Growth | This metric is central to TOI's value-based care strategy and delegated model expansion. Strong growth validates their ability to scale and manage risk, driving long-term profitability and market confidence. | 17.2% |
| Adjusted EBITDA | This is crucial as Q4 2025 marked TOI's first profitable quarter as a public company. Investors will closely watch Q1 2026's performance against the anticipated seasonal loss to gauge the trajectory towards full-year 2026 positive adjusted EBITDA. | 101.88% |
Key QuestionsCan The Oncology Institute achieve its full-year 2026 positive Adjusted EBITDA guidance and demonstrate a clear path to sustained free cash flow positivity by t
Can The Oncology Institute achieve its full-year 2026 positive Adjusted EBITDA guidance and demonstrate a clear path to sustained free cash flow positivity by the end of 2026, particularly after the anticipated Q1 2026 seasonal adjusted EBITDA loss?
- Question 2
Can The Oncology Institute continue to accelerate its delegated capitation model expansion, particularly with Elevance Health and new partners like Humana/CarePlus, to achieve its $150 million capitated revenue guidance for 2026, while maintaining expected Medical Loss Ratios (MLRs) to drive overall gross profit without an aggregate dip?
- Question 3
Will the launch of the new network portal in Q2 2026 and the continued implementation of AI-related efficiencies deliver the projected $2 million in SG&A savings for 2026, and can the pharmacy business sustain its strong revenue run rate and achieve modest incremental growth from new capitation lives as guided?
Rerating Thresholds
| Metric | What'S Needed For Rerating | Why It Matters | Earnings Date |
|---|---|---|---|
| Pharmacy Revenue Growth | For The Oncology Institute (TOI) stock to rerate higher, Pharmacy Revenue Growth needs to demonstrate continued strong momentum, ideally sustaining year-over-year growth above 40%. More critically, this growth must translate into the company achieving positive Adjusted EBITDA for Q4 2025 (between breakeven and positive $2 million) and providing a clear path to the higher end of its full-year 2026 Adjusted EBITDA guidance ($0 million to $9 million). Additionally, exceeding the upper end of the reaffirmed full-year 2025 total revenue guidance of $505 million would be a significant positive catalyst. | Hitting these thresholds validates TOI's value-based care model and its ability to monetize proprietary data and integrated pharmacy services. Sustained high pharmacy revenue growth, coupled with achieving and expanding Adjusted EBITDA profitability, signals that operational efficiencies (including AI initiatives) are working, improving its competitive position and moving towards a sustainable, cash-flow positive business, thereby justifying a higher valuation. This aligns with the 'MedTech Long '25: HC Data & Services' thesis, which emphasizes expanding EBITDA margins and AI-driven data liquidity. | 2026-03-05 |
| Total Revenue | For The Oncology Institute, Inc. (TOI) stock to rerate higher, the company needs to report full-year 2026 Total Revenue in the range of $660 million to $675 million. This would significantly exceed the company's current 2026 guidance of $630 million to $650 million and analyst projections for 31% revenue growth. This revenue performance must be coupled with achieving positive Adjusted EBITDA for Q4 2025 (guidance $0-$2 million) and providing a confident outlook for positive full-year 2026 Adjusted EBITDA ($0-$9 million) and a clear path to positive free cash flow in 2026. | Exceeding revenue targets and achieving profitability validates TOI's AI-driven, value-based care model, addressing financial concerns. This demonstrates strong execution, strengthens its competitive position, and could lead to a re-evaluation of its depressed valuation, driving a positive stock rerating. | 2026-03-05 |
| Capitated Revenue Growth | For The Oncology Institute (TOI) stock to rerate higher, Capitated Revenue Growth needs to exceed the current 38.9% (Q3 2025 rate) and demonstrate strong progress towards, and ideally surpass, the company's 2026 target of approximately $150 million in capitated revenue, implying a growth rate of at least 45% year-over-year. This acceleration in growth is crucial to validate the expansion of its delegated capitation model, particularly with partners like Elevance Health. | Hitting this threshold is crucial as it validates TOI's core strategy of scaling its value-based oncology care model and expanding Medicare Advantage bundles. Strong capitated revenue growth demonstrates successful execution, enhances the company's competitive position, and signals future profitability, which are key drivers for investor confidence and a positive stock rerating. | 2026-03-05 |
Earnings Transcript Summary
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Scaling and driving profitability in the value-based care platform: Management highlighted achieving their first profitable quarter as a public company from an adjusted EBITDA perspective in Q4 2025 and reaffirmed expectations for full-year positive adjusted EBITDA in 2026, driven by the expansion of their capitated care model, particularly through delegated arrangements. 2. Launching a proprietary new network portal in Q2 2026: This platform is intended to strengthen engagement with affiliated and independent providers, improve visibility into utilization management pathways, support formulary adherence, drive continuous improvement in medical loss ratio, and enable ancillary services engagement like Part D dispensing. 3. Strengthening the leadership team and Board of Directors: Management emphasized the additions of Jeffrey Langsam as Chief Clinical Officer and Kristin England as Chief Administrative Officer in 2025, and Mark Stolper and Kim Tzoumakas to the Board in Q1 2026, to bring significant experience and valuable perspectives for scaling the organization and executing on growth strategy. | The overall takeaway of the call was highly positive and confident. The Oncology Institute achieved a significant milestone by reporting its first profitable quarter as a public company from an adjusted EBITDA perspective in Q4 2025, alongside strong top-line growth across all segments, particularly in pharmacy revenue. Management reaffirmed robust guidance for 2026, projecting full-year positive adjusted EBITDA and free cash flow positivity by the end of the year, driven by the expanding delegated capitation model and operational efficiencies from AI. The tone was optimistic, emphasizing strong execution, strategic growth initiatives, and a unique care model that positions TOI favorably even amidst broader industry dynamics like Medicare Advantage rate changes. | For Q3 2025, total revenue increased 36.7% year-over-year. Patient services revenue increased 21% year-over-year. Capitated revenue increased 38.9% year-over-year. Pharmacy revenue increased 57.4% year-over-year. Fee-for-service business grew 13% year-over-year. | 1. Q4 2025 dispensing revenue drivers and 2026 expectations: Analysts inquired about the higher-than-modeled dispensing revenue in Q4. Management attributed this to strong operational execution in mitigating script leakage and robust patient encounter growth from capitated contracts. For 2026, they anticipate pharmacy performance in line with the second half of 2025 run rate, plus modest incremental growth from new capitation lives. 2. Expansion of Elevance and Humana contracts and the Total Addressable Market (TAM): Analysts asked about the goal to double the Elevance contract in Florida and the new Humana/CarePlus contracts. Management confirmed the goal for Elevance and stated the Humana and CarePlus contracts were new, effective in Q4 2025, and represented significant opportunity given the large Medicare Advantage penetration in Florida. 3. Capitated revenue margins (MLR), volumes, cost trends, and the impact of the 2027 Medicare Advantage rate notice: Analysts questioned MLR performance and potential profit margin dips with new delegated contracts. Management stated that performance in terms of volume and MLR was as expected, with real-time views into claims for effective MLR management. They clarified that while delegated contracts might have a slightly higher initial MLR, it would not cause a dip in the total weighted gross margin. Regarding the MA rate notice, management explained that pressure on payers is a 'tailwind for TOI' because their top-line Medicare Advantage reimbursement is not a percentage of total premium and is not impacted by risk adjustment, leading payers to seek TOI's value proposition. | For the full year 2025, total revenue increased approximately 27.8% year-over-year to $502.7 million. Fee-for-service business grew 9% year-over-year to $148.5 million. Capitation business grew 17.2% year-over-year to $80.5 million. Pharmacy revenue grew 49.6% year-over-year to $269.2 million. For the fourth quarter of 2025, total revenue increased 41.6% year-over-year to $142 million. Patient services revenue (including capitation and fee-for-service) increased 19.2% year-over-year to $59.8 million. Pharmacy revenue increased 71.1% year-over-year to $81.4 million. |
· 2025Q3 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Achieving and sustaining profitability: Management is focused on achieving adjusted EBITDA profitability in the fourth quarter of 2025 and becoming free cash flow positive in 2026, having already achieved adjusted EBITDA profitability for the first month as a public company in September. 2. Expanding the delegated capitation model and MSO network: There is a strong focus on growing the delegated capitation model, particularly in Florida with Elevance Health, which is more than doubling the relationship, and expanding the MSO network to over 200 providers. 3. Implementing AI for operational efficiencies: Management is actively launching and scaling AI enablement efforts in revenue cycle management, prior authorization services, and patient call centers, expecting significant operating expense efficiencies and improved staff productivity. | The overall takeaway of the call was highly positive and confident. The Oncology Institute demonstrated very strong top-line growth across all business lines in Q3 2025, with significant acceleration in pharmacy and capitated revenue. Management highlighted achieving the first month of adjusted EBITDA profitability in September and raised its full-year 2025 guidance, reinforcing confidence in achieving overall profitability in Q4 and positive free cash flow in 2026. The tone was optimistic, emphasizing strong momentum, successful execution of strategic initiatives like the expansion of the delegated capitation model, and the promising early results from AI implementation for operational efficiencies, despite acknowledging a one-time reserve and a cybersecurity incident. | For Q2 2025, total revenue grew 21.5% year-over-year, indicating an acceleration in Q3. Pharmacy revenue grew 41% year-over-year, also showing acceleration in Q3. Patient services revenue grew 7% year-over-year, accelerating to 21% in Q3. Fee-for-service revenue grew 10% year-over-year, accelerating to 13% in Q3. Specific year-over-year capitated revenue growth for Q2 was not explicitly stated as a percentage in the provided snippets, but the addition of over 50,000 new capitated lives was noted. | 1. **Impact of the $1.8 million reserve on adjusted EBITDA and future quarters:** Management clarified that the $1.8 million reserve was a one-time catch-up adjustment against fee-for-service revenue and was included in the reported adjusted EBITDA, meaning the normalized loss would have been $1.7 million. They do not expect a material impact on fee-for-service revenue recognition going forward. 2. **Sustainability of September's profitability and outlook for Q4 and 2026 free cash flow:** Management stated they are fully expecting breakeven adjusted EBITDA for Q4 and anticipate full-year positive adjusted EBITDA in 2026. They also expect positive free cash flow in Q4 2025, with run-rate free cash flow positivity projected for mid-2026. 3. **Details on delegated contract MLRs and why TOI manages trends better than MA plans:** Management explained that the overall MLR for TOI is in the high 60s, with the delegated model typically in the mid-70s and the narrow network model in the mid-60s. They attributed their ability to manage trends better to their unique care delivery model, which combines employed clinics and providers with a wrap network of non-employee providers, allowing for greater control over care consistency, NCCN guideline adherence, and prescribing patterns. | Total revenue increased 36.7% year-over-year. Patient services revenue (including capitation and fee-for-service) increased 21% year-over-year. Capitated revenue increased 38.9% year-over-year. Pharmacy revenue increased 57.4% year-over-year. Fee-for-service business grew 13% year-over-year. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| The Oncology Institute is expanding its capitated care model, particularly through delegated arrangements, initiating 9 new capitated contracts in 2025 across California, Florida, and Nevada, covering approximately 260,000 additional patient lives. The delegated capitation partnership with Elevance in Florida is on track to more than double in 2026, with approximately 70,000 lives currently under capitated arrangements within this partnership. New capitation agreements were also initiated with Humana and CarePlus in Florida during Q4 2025, adding approximately 22,000 Medicare Advantage lives in South Florida. The Florida Oncology network platform grew to approximately 207 participating physicians and advanced practice providers. The company sees a 'tremendous opportunity' for growth in the MA market in Florida, representing 'many multiples of our current capitated revenue'. For 2026, the company has a healthy pipeline within existing markets and does not need to expand beyond current markets to meet its capitated revenue guidance. | The Oncology Institute highlights its 'very unique care model' combining employed and network providers in markets with population-level Part B capitation. This model allows for stronger control over practice patterns, enabling TOI to 'price contracts more competitively' and be 'truly the best alternative for a payer' from both pricing and care coordination perspectives. The company does not take risk on CAR T therapy due to its low incidence and limited community locations, but acknowledges 'interesting businesses out there that are trying to develop models for CAR T therapy in the community'. | The company expects the impact of the Inflation Reduction Act (IRA) on IMBRUVICA in 2026 to be minor, less than 1% of total pharmacy revenue and gross margin. TOI has multiple levers to offset future IRA impacts, including optimizing pharmacy mix and leveraging purchasing power, and does not expect the IRA to materially alter its long-term economics. The Medicare Advantage (MA) rate cycle and associated pressure on health plans and full-risk medical groups is viewed as a 'tailwind for TOI', as TOI's top-line MA reimbursement is not a percentage of total premium or impacted by risk adjustment. Pressure on payers generally leads them to proactively seek partners for quality care, access, and utilization improvement. Most of TOI's contracts include PMPM (Per Member Per Month) escalators. The oncology care market is highly competitive, with evolving payer dynamics and potential pressures from drug reimbursement policy changes, prior authorization regulations, or increased competition. | The Oncology Institute is reaffirming its expectation to achieve full-year positive adjusted EBITDA in 2026 and expects to achieve free cash flow positivity by the end of 2026. The company guided for 2026 revenue in the range of $630 million to $650 million, approximately $150 million of which will be capitated revenue (representing over 80% growth). Gross profit is projected between $97 million and $107 million, and adjusted EBITDA between $0 million and $9 million. Free cash flow is guided to be negative $15 million to $5 million. The first quarter of 2026 is anticipated to be the lowest seasonally, with an expected adjusted EBITDA loss of $3 million to $1 million. A proprietary new network portal is set to launch in Q2 2026 to strengthen provider engagement and improve utilization management. AI-related efficiencies across prior authorization, call center, and RCM are expected to generate approximately $2 million in SG&A savings in 2026. SG&A as a percentage of revenue is expected to trend down modestly to approximately 16%. | HC | The Medicare Advantage rate cycle, often perceived as a headwind for value-based care, is seen as a tailwind for TOI, as pressure on payers drives them to seek partners for utilization improvement. The Inflation Reduction Act's impact on drug pricing is minor for TOI, which has levers to offset future effects. | first profitable quarter as a public company from an adjusted EBITDA perspective. revenue increasing approximately 28% year-over-year and surpassing $500 million for the first time. reaffirming our expectation to achieve full year positive adjusted EBITDA in 2026. Elevance in Florida... remains on track to continue expansion across the state in 2026, which would more than double the current partnership. The MA rate cycle... is actually a tailwind for TOI. | expected impact of the Inflation Reduction Act... representing an unfavorable impact of less than 1% of total pharmacy revenue and gross margin. the first quarter is seasonally our lowest due to patient deductible resets and annual drug price increases. anticipate first quarter adjusted EBITDA to be between a loss of $3 million to $1 million. some minor cannibalization of fee-for-service volumes. | The leadership team was strengthened in 2025 with the additions of Jeffrey Langsam as Chief Clinical Officer and Kristin England as Chief Administrative Officer. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| The Oncology Institute is expanding its delegated capitation model in Florida, which is expected to more than double its relationship with Elevance Health in Q4 through additional Medicare Advantage lives in Central Florida. The MSO network in Florida has expanded to over 200 providers. New capitation contracts signed in 2025 are estimated to contribute $19 million of full-year revenue, representing a 29% increase over 2024 capitated revenue. The delegated model is anticipated to become the most prominent across all markets, addressing a larger Total Addressable Market (TAM) in a capital-effective manner. The company sees no slowdown in opportunities for value-based contracting across markets. | The Oncology Institute's unique care delivery model, which includes a backbone of employed clinics and providers with a wrap network of non-employee providers, offers a greater degree of control over consistency of care and adherence to NCCN guidelines, providing a differential ability to drive better value for patients and payers. The community-based ability to provide radiopharmaceuticals like Pluvicto is considered a distinct advantage. | Managed care plans are facing significant pressure on their Medical Loss Ratios (MLRs). The overall macro landscape for drugs is trending towards lowering costs for patients and simplifying the drug reimbursement process. Changes from the IRA and other policies are viewed as net positive for TOI, as they generally lower the unit cost of drugs and enhance accessibility. The industry is experiencing very high medical utilization, particularly in oncology. Most of TOI's contracts include PMPM (Per Member Per Month) escalators, allowing for annual increases. | The Oncology Institute expects to achieve profitability in Q4 2025 and become free cash flow positive in 2026. Margins on new capitation contracts are projected to mature to target over the next few quarters. The agentic AI model for authorizations is expected to be fully transitioned in Q4, reducing submission time from 18 minutes to approximately 5 seconds and delivering over 80% savings per authorization. AI authorization efficiencies are projected to yield up to $2 million in operating expense savings, with expansion to other functions in 2026. For 2026, the company anticipates top-line growth exceeding 20%, with subtle improvement to gross margin and a relatively flat SG&A percentage of revenue. | Data | "delivering strong results across all areas of the business" "achieved adjusted EBITDA profitability for our first month as a public company in September." "reinforcing our expectation to achieve profitability in the fourth quarter and become free cash flow positive in 2026." "more than doubles our relationship with this payer in less than a year" "savings per auth of over 80%" "opens a massive new TAM of value-based contract growth in upcoming years." "Pharmacy revenue... increased 57.4% year-over-year" "SG&A... reduction of approximately 820 basis points versus a year ago." "raising our guidance ranges for the full year of 2025" "phenomenal success growing our capitated business. We expect that growth rate to continue, if not accelerate" | "Adjusted EBITDA loss of $3.5 million in Q3" "cybersecurity incident at one of our key vendors" "experienced a period where we were unable to bill for fee-for-service claims" "event will influence collections in late Q4 and early Q1" "Cash flow from operations was negative $27.8 million" "capitation margin declined modestly year-over-year due to the ramp of new delegated contracts with typical MLRs beginning at low margins." "recorded a $1.8 million reserve against fee-for-service revenue in the third quarter." |
Earnings ResultsThe company reported strong Q4 2025 pharmacy revenue growth of 71.1% year-over-year, significantly exceeding the 40% threshold. Additionally, TOI achieved posit
| Metric | Prior Quarter | Rerating Trigger | Actual Reported | Hit Target? | Notes |
|---|---|---|---|---|---|
| Pharmacy Revenue Growth | 57.4% | For The Oncology Institute (TOI) stock to rerate higher, Pharmacy Revenue Growth needs to demonstrate continued strong momentum, ideally sustaining year-over-year growth above 40%. More critically, this growth must translate into the company achieving positive Adjusted EBITDA for Q4 2025 (between breakeven and positive $2 million) and providing a clear path to the higher end of its full-year 2026 Adjusted EBITDA guidance ($0 million to $9 million). Additionally, exceeding the upper end of the reaffirmed full-year 2025 total revenue guidance of $505 million would be a significant positive catalyst. | Q4 2025: $81.4 million (71.1% y/y growth) | Yes | The company reported strong Q4 2025 pharmacy revenue growth of 71.1% year-over-year, significantly exceeding the 40% threshold. Additionally, TOI achieved positive Adjusted EBITDA of $147,000 in Q4 2025, which falls within the guidance range of breakeven to positive $2 million. The full-year 2026 Adjusted EBITDA guidance of $0 million to $9 million was also reaffirmed. Full-year 2025 total revenue was $502.7 million, slightly below the upper end of the reaffirmed guidance of $505 million. |
| Total Revenue | 36.7% | For The Oncology Institute, Inc. (TOI) stock to rerate higher, the company needs to report full-year 2026 Total Revenue in the range of $660 million to $675 million. This would significantly exceed the company's current 2026 guidance of $630 million to $650 million and analyst projections for 31% revenue growth. This revenue performance must be coupled with achieving positive Adjusted EBITDA for Q4 2025 (guidance $0-$2 million) and providing a confident outlook for positive full-year 2026 Adjusted EBITDA ($0-$9 million) and a clear path to positive free cash flow in 2026. | Full-year 2025: $502.7 million (27.8% y/y growth) | No | Full-year 2025 total revenue was $502.7 million, representing 27.8% year-over-year growth. The rerating trigger for Total Revenue is for full-year 2026, requiring a range of $660 million to $675 million. The company's guidance for full-year 2026 revenue is $630 million to $650 million, which falls below the rerating threshold. However, the company did achieve positive Adjusted EBITDA in Q4 2025 ($147,000) and reaffirmed its full-year 2026 Adjusted EBITDA guidance ($0 million to $9 million) and expectation for free cash flow positivity by the end of 2026. |
| Capitated Revenue Growth | 38.9% | For The Oncology Institute (TOI) stock to rerate higher, Capitated Revenue Growth needs to exceed the current 38.9% (Q3 2025 rate) and demonstrate strong progress towards, and ideally surpass, the company's 2026 target of approximately $150 million in capitated revenue, implying a growth rate of at least 45% year-over-year. This acceleration in growth is crucial to validate the expansion of its delegated capitation model, particularly with partners like Elevance Health. | Full-year 2025: $80.5 million (17.2% y/y growth) | Yes | Full-year 2025 capitated revenue grew 17.2% year-over-year to $80.5 million. Although this was below the prior quarter's growth rate of 38.9%, the company reaffirmed its 2026 guidance for approximately $150 million in capitated revenue. This guidance implies an 86.3% year-over-year growth from 2025, which well exceeds the 'at least 45% year-over-year' implied by the rerating trigger for 2026, demonstrating strong progress towards and surpassing the target. Management highlighted continued expansion of the delegated capitation model, including the goal to more than double the Elevance partnership in Florida in 2026. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | IS CHANGE | Price Reaction |
|---|---|---|---|---|---|---|
| 2026-03-12 | The Oncology Institute achieved its first profitable adjusted EBITDA quarter as a public company in Q4 2025, reaffirming 2026 full-year profitability and strong capitated model expansion, including doubling the Elevance partnership. The market reacted very positively, with the stock significantly outperforming SPY (8.40% vs 0.45%) post-earnings, reflecting confidence in TOI's growth strategy and path to sustainable profitability. | Earnings Transcript | Neutral | False | +8.40% (vs SPY: +7.95%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| TOI_8fe682de | In Q4 2025 | 2025-10-01 | 2025-12-31 | Full transition of TOI's central business office operations, including patient intake, billing, and prior-authorizations, to an agentic AI model in Q4 2025, with expansion to additional authorization functions in 2026. | Drives material OpEx savings (up to $2 million in authorization efficiencies) and frees hundreds of staff hours for patient care, improving margins and scalability. | Ticker | 2025-11-13 | earnings_transcript |
| TOI_977aac49 | In Q4 2025 | 2025-10-01 | 2025-12-31 | Expansion of Elevance Health capitation lives in Central Florida; additional Medicare Advantage MA lives under capitation to TOI, more than doubling the payer relationship. | Significantly expands capitation revenue and scale, potentially improving profitability and cash flow through larger, managed-care contracts. | Ticker | 2025-11-13 | earnings_transcript |
| TOI_ee7fc2a0 | Q4 2025 | 2025-10-01 | 2025-12-31 | Fourth-quarter 2025 adjusted EBITDA is expected to be breakeven to positive up to $2 million per management guidance. | A profitability milestone that could unlock improved investor sentiment and valuation; supports 2026 profitability trajectory. | Ticker | 2025-11-13 | earnings_transcript |
| TOI_1f5eda90 | In 2026 | 2026-01-01 | 2026-12-31 | TOI targets free cash flow positive in 2026 as it scales operations and benefits from AI-enabled efficiencies and growing capitated revenue. | Key cash-flow milestone potentially enabling debt reduction, reinvestment, and valuation upgrade. | Ticker | 2025-11-13 | earnings_transcript |
| TOI_b09dfac0 | Late Q4 2025 to early Q1 2026 | 2025-12-01 | 2026-02-28 | Vendor cybersecurity incident disrupted billing for fee-for-service claims; expected to create collections lag as submitted claims are caught up in late Q4 2025 and early Q1 2026. | Near-term working-capital pressure and potential interim cash-flow impact; management indicates limited disruption and resilience. | Ticker | 2025-11-13 | earnings_transcript |
| TOI_8d2c1227 | full year positive adjusted EBITDA in 2026 | 2026-01-01 | 2026-12-31 | Achievement of full year positive adjusted EBITDA for 2026. | This is a key financial milestone indicating sustainable profitability and will significantly impact investor sentiment and valuation. | Ticker | 2026-03-12 | earnings_transcript |
| TOI_06d1356f | continue expansion across the state in 2026, which would more than double the current partnership. | 2026-01-01 | 2026-12-31 | Expansion of the delegated capitation partnership with Elevance in Florida, aiming to more than double the current partnership in 2026. | This expansion is a significant driver of capitated revenue growth and validates the success of TOI's delegated model, impacting top-line growth and market penetration. | Ticker | 2026-03-12 | earnings_transcript |
| TOI_5704e912 | over 80% growth in capitated revenue for the year | 2026-01-01 | 2026-12-31 | Achieving over 80% growth in capitated revenue for the full year 2026. | This is a core growth driver for TOI's value-based care model, directly impacting revenue, profitability, and investor confidence in the company's strategic direction. | Ticker | 2026-03-12 | earnings_transcript |
| TOI_d7b60b8a | launch a proprietary new network portal in Q2 | 2026-04-01 | 2026-06-30 | Launch of a proprietary new network portal in Q2 2026. | This portal is expected to improve provider engagement, utilization management, formulary adherence, and drive ancillary services engagement, potentially improving MLR and incremental growth. | Ticker | 2026-03-12 | earnings_transcript |
| TOI_0aa47467 | For full year 2026 | 2026-01-01 | 2026-12-31 | Achievement of full year 2026 financial guidance: revenue ($630M-$650M), capitated revenue (~$150M), gross profit ($97M-$107M), and adjusted EBITDA ($0M-$9M). | Meeting or exceeding this guidance is crucial for investor confidence, validating the company's growth strategy and path to profitability, directly impacting valuation. | Ticker | 2026-03-12 | earnings_transcript |
| TOI_31488436 | first quarter adjusted EBITDA to be between a loss of $3 million to $1 million | 2026-01-01 | 2026-03-31 | Q1 2026 Adjusted EBITDA performance, anticipated to be a loss between $3 million and $1 million. | Performance relative to this guidance will influence investor sentiment regarding the company's quarterly trajectory towards full-year profitability and the impact of seasonal factors. | Ticker | 2026-03-12 | earnings_transcript |
| TOI_a9d546cc | Exiting and second half of the year [2026] | 2026-07-01 | 2026-12-31 | Achieving free cash flow positivity by the end of 2026. | This is a critical financial milestone demonstrating the company's ability to generate cash from operations, reducing reliance on external financing and significantly boosting investor confidence. | Ticker | 2026-03-12 | earnings_transcript |
| TOI_4b0698eb | in 2026 | 2026-01-01 | 2026-12-31 | Realization of approximately $2 million in SG&A savings from AI-related efficiencies across prior authorization, call center, and RCM in 2026. | Achieving these savings demonstrates the successful implementation and scaling of AI, contributing to margin expansion and operational leverage, which is a key bull point for the company. | Ticker | 2026-03-12 | earnings_transcript |